HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SKYE

Skye Bioscience Inc

Last Close
Aug 22 • 04:00PM ET
3.29
Dollar change
-0.26
Percentage change
-7.32 		%
Healthcare • Biotechnology • USA • NASD
Peers: NBIX PCRX ACAD BMRN MDGL PRGO XENE CRIS VNDA TBPH
 | Held by: VTI VXF IWC MSSM
Index- P/E- EPS (ttm)-1.07 Insider Own42.35% Shs Outstand30.99M Perf Week-6.27%
Market Cap101.95M Forward P/E- EPS next Y-1.31 Insider Trans-3.41% Shs Float17.86M Perf Month-17.96%
Enterprise Value53.73M PEG- EPS next Q-0.30 Inst Own27.40% Short Float15.16% Perf Quarter58.94%
Income-42.37M P/S- EPS this Y-86.73% Inst Trans-15.75% Short Ratio3.00 Perf Half Y10.40%
Sales0.00M P/B2.33 EPS next Y3.98% ROA-60.78% Short Interest2.71M Perf YTD16.25%
Book/sh1.41 P/C2.10 EPS next 5Y- ROE-72.75% 52W High7.47 -55.96% Perf Year-37.45%
Cash/sh1.57 P/FCF- EPS past 3/5Y48.21% 42.99% ROIC-96.63% 52W Low1.14 188.60% Perf 3Y-51.71%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.47% 8.79% Perf 5Y-75.17%
Dividend TTM- EV/Sales- EPS Y/Y TTM72.65% Oper. Margin- ATR (14)0.33 Perf 10Y-99.49%
Dividend Ex-Date- Quick Ratio6.09 Sales Y/Y TTM- Profit Margin- RSI (14)44.67 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio6.09 EPS Q/Q-117.42% SMA20-6.08% Beta2.35 Target Price15.00
Payout- Debt/Eq0.01 Sales Q/Q- SMA50-7.45% Rel Volume0.54 Prev Close3.55
Employees16 LT Debt/Eq0.00 EarningsAug 07 AMC SMA20010.49% Avg Volume901.89K Price3.29
IPONov 26, 2014 Option/ShortYes / Yes EPS/Sales Surpr.-37.50% - Trades Volume487,557 Change-7.32%
Date Action Analyst Rating Change Price Target Change
Aug-15-25Initiated Evercore ISI Outperform $10
Feb-28-25Initiated William Blair Outperform
Sep-30-24Initiated Scotiabank Sector Outperform $20
Sep-10-24Initiated JMP Securities Mkt Outperform $15
Jul-09-24Initiated Craig Hallum Buy $18
May-23-24Initiated Cantor Fitzgerald Overweight $21
Apr-12-24Initiated Oppenheimer Outperform $25
Aug-21-25 07:00AM
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
(GlobeNewswire)
Aug-08-25 07:00AM
Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...
(GuruFocus.com)
Aug-07-25 04:01PM
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
(GlobeNewswire) -8.74%
Jul-30-25 07:00AM
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
(GlobeNewswire)
Jul-06-25 04:01AM
Skye Bioscience Highlights Nimacimab's Promise in Obesity Treatment, Anticipates Phase 2a Data
(Insider Monkey)
07:00AM Loading…
Jun-23-25 07:00AM
Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
(GlobeNewswire) +32.87%
Jun-22-25 06:15AM
Analysts Predict Up to ~590% Spike for These 2 Strong Buy Penny Stocks
(TipRanks)
Jun-17-25 07:00AM
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
(GlobeNewswire)
May-23-25 11:13AM
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
(Zacks) -8.21%
May-22-25 07:00AM
Skye Bioscience to Participate in Upcoming Investment Conferences
(GlobeNewswire) -6.33%
May-19-25 05:00AM
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
(GlobeNewswire) +14.97%
May-13-25 04:05PM
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.37%
07:00AM
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
(GlobeNewswire)
May-09-25 03:40AM
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ...
(GuruFocus.com)
May-08-25 04:01PM
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
(GlobeNewswire)
07:00AM Loading…
May-07-25 07:00AM
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
(GlobeNewswire)
Apr-29-25 07:00AM
Skye Bioscience to Participate in May Investment and Medical Conferences
(GlobeNewswire)
Apr-25-25 08:06PM
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-16-25 07:50AM
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
(Seeking Alpha) -7.60%
Apr-15-25 07:00AM
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
(GlobeNewswire) +30.53%
Apr-14-25 07:00AM
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
(GlobeNewswire) -7.09%
Mar-20-25 09:59PM
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period
(SeekingAlpha) -5.50% +19.05%
09:58PM
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
(SeekingAlpha)
04:01PM
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
(GlobeNewswire)
10:00AM
Here are the major earnings after the close today
(SeekingAlpha)
Mar-19-25 05:35PM
Skye Bioscience Q4 2024 Earnings Preview
(SeekingAlpha) -12.66%
Mar-14-25 07:00AM
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
(GlobeNewswire)
Feb-27-25 06:00PM
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +6.34%
Feb-24-25 07:00AM
Skye Bioscience to Participate in SXSW Session on Obesity
(GlobeNewswire)
Feb-20-25 07:00AM
Skye Bioscience to Present at TD Cowen Health Care Conference
(GlobeNewswire)
07:00AM Loading…
Feb-04-25 07:00AM
Skye Bioscience Announces Participation in February Conferences
(GlobeNewswire)
Jan-13-25 07:00AM
Skye Bioscience Provides 2025 Look Ahead and Year in Review
(GlobeNewswire)
Dec-19-24 07:00AM
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
(GlobeNewswire)
Nov-18-24 07:00AM
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
(GlobeNewswire) -7.88%
Nov-15-24 07:45AM
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
(TipRanks) -10.16%
Nov-14-24 07:00AM
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
(GlobeNewswire)
Nov-07-24 04:01PM
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
(GlobeNewswire)
Nov-04-24 07:00AM
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
(GlobeNewswire)
Nov-01-24 07:00AM
Skye Bioscience to Announce Third Quarter 2024 Results
(GlobeNewswire) +6.11%
Oct-29-24 07:00AM
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
(GlobeNewswire)
Oct-21-24 07:00AM
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
(GlobeNewswire)
Sep-23-24 07:00AM
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
(GlobeNewswire) +11.15%
Sep-03-24 07:00AM
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
(GlobeNewswire)
Aug-26-24 07:00AM
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
(GlobeNewswire) +15.29%
Aug-23-24 06:45PM
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +12.69%
Aug-22-24 07:00AM
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
(GlobeNewswire)
Aug-09-24 05:59PM
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
(GlobeNewswire) -9.42%
Jul-24-24 07:30AM
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity
(GlobeNewswire)
06:00AM
Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
(GlobeNewswire)
Jul-11-24 07:15AM
Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th
(GlobeNewswire) +6.90%
07:00AM
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
(GlobeNewswire)
Jul-03-24 07:00AM
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
(GlobeNewswire)
Jul-01-24 11:13AM
Google DeepMind CEO: 'This Is the Next $100 Billion AI Business'
(InvestorPlace)
07:00AM
Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes
(GlobeNewswire)
Jun-25-24 07:00AM
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
(GlobeNewswire) -6.19%
Jun-10-24 08:22AM
Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail
(FierceBiotech.com) -8.78%
07:00AM
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
(GlobeNewswire)
Jun-03-24 07:00AM
Skye Bioscience to Present at Jefferies Global Healthcare Conference
(GlobeNewswire)
May-17-24 04:12PM
Google DeepMind CEO: 'This Is the Next $100 Billion AI Business'
(InvestorPlace)
May-10-24 07:00AM
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
(GlobeNewswire) -6.21%
May-07-24 11:59AM
Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program
(News Direct)
Apr-30-24 07:00AM
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
(GlobeNewswire)
Apr-23-24 07:00AM
Skye Bioscience to Present at Upcoming Investment Conferences
(GlobeNewswire) -5.27%
Apr-10-24 08:00AM
Skye Bioscience Uplists to The Nasdaq Global Market
(GlobeNewswire) +39.69%
Mar-11-24 09:20AM
Skye Bioscience Announces $40 Million Private Placement Equity Financing
(Newsfile) -24.95%
Mar-04-24 07:00AM
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
(GlobeNewswire) +7.59%
Feb-26-24 07:00AM
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
(GlobeNewswire) +13.82%
Feb-07-24 07:00AM
Skye Bioscience to Present at Oppenheimer Investor Conference
(Newsfile) -7.55%
Jan-29-24 08:00AM
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
(Newsfile) +29.03%
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab Andrew J.DirectorAug 22 '25Sale3.42170,449582,93657,493Aug 22 07:07 PM
Schwab Andrew J.DirectorAug 21 '25Sale3.5760,956217,61363,963Aug 22 07:07 PM
5AM Partners VII, LLC10% OwnerAug 22 '25Sale3.42170,449582,93657,493Aug 22 07:05 PM
5AM Partners VII, LLC10% OwnerAug 21 '25Sale3.5760,956217,61363,963Aug 22 07:05 PM
Diep Tuan TuChief Development OfficerNov 18 '24Sale4.9919,48997,25082,259Nov 20 08:23 AM
Diep Tuan TuChief Development OfficerNov 15 '24Sale5.5585472101,748Nov 20 08:23 AM
ARSENAULT KAITLYNChief Financial OfficerNov 18 '24Sale4.9943,206215,598166,342Nov 19 09:57 PM
ARSENAULT KAITLYNChief Financial OfficerNov 15 '24Sale5.551901,054209,548Nov 19 09:57 PM
DHILLON PUNITChief Executive OfficerNov 18 '24Sale4.9982,546411,905329,823Nov 19 09:20 PM
DHILLON PUNITChief Executive OfficerNov 15 '24Sale5.553642,020412,369Nov 19 09:20 PM
Grayson Paul A.DirectorNov 18 '24Sale4.9986,244430,358259,701Nov 19 09:14 PM
Grayson Paul A.DirectorNov 15 '24Sale5.553071,704345,945Nov 19 09:14 PM
ARSENAULT KAITLYNOfficerNov 15 '24Proposed Sale5.5157,084314,533Nov 15 05:31 PM
DHILLON PUNITOfficerNov 15 '24Proposed Sale5.51100,693554,818Nov 15 05:28 PM
Diep Tuan TuOfficerNov 15 '24Proposed Sale5.5122,877126,052Nov 15 05:25 PM
Grayson Paul A.DirectorNov 15 '24Proposed Sale5.5186,804478,290Nov 15 05:22 PM
Schwab Andrew J.DirectorSep 11 '24Sale6.60252,5001,666,50066,356Sep 13 06:56 PM
Schwab Andrew J.DirectorSep 13 '24Sale6.0613,83783,85266,277Sep 13 06:56 PM
5AM Partners VII, LLC10% OwnerSep 11 '24Sale6.60252,5001,666,50066,356Sep 13 06:54 PM
5AM Partners VII, LLC10% OwnerSep 13 '24Sale6.0613,83783,85266,277Sep 13 06:54 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

CAMP

CAMP4 Therapeutics Corp

Last Close
Aug 22 • 04:00PM ET
1.55
Dollar change
-0.04
Percentage change
-2.52 		%
Healthcare • Biotechnology • USA • NASD
CAMP CAMP4 Therapeutics Corp daily Stock Chart
Held by: VTI VXF IWC
Index- P/E- EPS (ttm)-2.57 Insider Own86.90% Shs Outstand20.16M Perf Week-7.19%
Market Cap31.25M Forward P/E- EPS next Y-2.20 Insider Trans0.00% Shs Float2.64M Perf Month-19.27%
Enterprise Value-0.58M PEG- EPS next Q-0.68 Inst Own8.11% Short Float9.38% Perf Quarter-22.69%
Income-51.78M P/S10.38 EPS this Y77.73% Inst Trans-12.01% Short Ratio1.95 Perf Half Y-67.78%
Sales3.01M P/B0.78 EPS next Y10.61% ROA- Short Interest0.25M Perf YTD-70.31%
Book/sh1.98 P/C0.80 EPS next 5Y44.38% ROE- 52W High12.30 -87.40% Perf Year-
Cash/sh1.94 P/FCF- EPS past 3/5Y-6.52% - ROIC-117.85% 52W Low1.30 18.77% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin44.50% Volatility13.10% 11.17% Perf 5Y-
Dividend TTM- EV/Sales-0.19 EPS Y/Y TTM- Oper. Margin-1785.10% ATR (14)0.18 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.60 Sales Y/Y TTM- Profit Margin-1722.08% RSI (14)47.95 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio5.60 EPS Q/Q-1.10% SMA20-2.21% Beta- Target Price15.25
Payout- Debt/Eq0.18 Sales Q/Q- SMA50-0.08% Rel Volume0.46 Prev Close1.59
Employees55 LT Debt/Eq0.10 EarningsAug 14 AMC SMA200-59.23% Avg Volume127.01K Price1.55
IPOOct 11, 2024 Option/ShortNo / Yes EPS/Sales Surpr.7.81% 161.80% Trades Volume58,577 Change-2.52%
Date Action Analyst Rating Change Price Target Change
May-27-25Initiated Wedbush Outperform $8
Nov-05-24Initiated William Blair Outperform
Nov-05-24Initiated Piper Sandler Overweight $18
Nov-05-24Initiated JP Morgan Overweight $23
Aug-14-25 04:05PM
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
(GlobeNewswire) +6.16% +7.74%
Jun-30-25 08:00AM
Sequans Appoints Jason W. Cohenour to Board of Directors
(Newsfile)
May-16-25 06:00AM
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
(GlobeNewswire) +9.52%
May-13-25 04:05PM
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
(GlobeNewswire) -7.92%
Apr-28-25 04:30PM
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
(GlobeNewswire) -10.00% -5.15%
11:00AM Loading…
Apr-05-25 11:00AM
Markets Watch Out For Core CPI With Big Banks Set To Report Earnings
(Seeking Alpha)
Mar-27-25 04:05PM
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
(GlobeNewswire) -10.16%
Mar-18-25 08:00AM
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
(GlobeNewswire)
Mar-04-25 05:24AM
CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025
(Insider Monkey) -5.27%
Feb-06-25 08:00AM
CAMP4 to Participate in Upcoming Investor Conferences
(GlobeNewswire) -6.95%
Jan-13-25 08:00AM
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Jan-07-25 04:05PM
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
(GlobeNewswire)
Dec-10-24 08:00AM
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
(GlobeNewswire) -8.08%
Dec-02-24 08:00AM
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
(GlobeNewswire) +5.85%
Nov-21-24 04:05PM
CAMP4 Reports Third Quarter 2024 Financial Results
(GlobeNewswire) +8.44% -6.40%
07:07PM Loading…
Oct-10-24 07:07PM
CAMP4 Announces Pricing of Initial Public Offering
(GlobeNewswire)
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Northpond Ventures II GP, LLC10% OwnerOct 15 '24Buy11.00763,6368,399,996763,636Oct 17 06:34 PM
AH Equity Partners Bio I, L.L.10% OwnerOct 15 '24Buy11.00727,2727,999,9921,579,885Oct 17 05:05 PM
Enavate Sciences GP, LLC10% OwnerOct 15 '24Buy11.001,363,63614,999,9963,785,802Oct 17 04:15 PM
Polaris Management Co. VII, L.10% OwnerOct 15 '24Buy11.00909,0909,999,990909,090Oct 15 06:00 PM
5AM Partners VI, LLC10% OwnerOct 15 '24Buy11.00909,0909,999,9902,625,145Oct 15 05:56 PM
Nashat AmirDirectorOct 15 '24Buy11.00909,0909,999,990909,090Oct 15 05:49 PM
Schwab Andrew J.DirectorOct 15 '24Buy11.00909,0909,999,9902,625,145Oct 15 05:48 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.